11:09 EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fight
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron, Sanofi presents results from ADEPT Phase 2/3 trial on Dupixent
- Regeneron’s treatment of lipodystrophy granted FDA orphan designation
- Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab
- 3 Best Value Stocks to Buy Now, 2/27/2025, According to Analysts
- REGN Lawsuit Alert! Class Action Against Regeneron Pharmaceuticals, Inc.